A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

British Journal of Cancer

Volumn 69, Issue 1, 1994, Pages 196-199

  Lissoni, P ^a   Barni, S ^a   Tancini, G ^a   Ardizzoia, A ^a   Ricci, G ^b   Aldeghi, R ^c   Brivio, F ^d   Tisi, E ^e   Rovelli, F ^a   Rescaldani, R ^a   Quadro, G ^f   Maestroni, G ^g  

^a Ist Naz Stud/Cura Tumori   (Italy)

^b Divisione di Geriatria ^*  (Italy)

^c Ist Naz Stud e la Cura dei Tumori   (Italy)

^d Divisione di Chirurgia Generale ^*  (Italy)

^e SAN GERARDO HOSPITAL   (Italy)

^f Medea Research   (Italy)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MELATONIN; NEOPTERIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; EOSINOPHIL; FEMALE; FEVER; HUMAN; KIDNEY CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYALGIA; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TUMOR REGRESSION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MELATONIN; MIDDLE AGED; NEOPLASMS;

EID: 0028115805     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.34     Document Type: Article

References (14)

1. ATZPODIEN, J. & KIRCHNER, H. (1990). Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin. Wochenschr., 68, 1–11.
2. ATZPODIEN, J., KORFER, A., FRANKS, C.R., POLIWODA, H. & KIRCHNER, H. (1990). Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet, i, 1509–1512.
3. BRODER, S., MUUL, L. & WAIDMANN, T.A. (1978). Suppressor cells in neoplastic disease. J. Natl Cancer Inst., 61, 5–11.
4. DENICOFF, K.D., DURKIN, T.M., LOTZE, M.T., QUINLAN, P.E., DAVIS, C.L., LISTWAK, S.J., ROSENBERG, S.A. & RUBINOW, D.R. (1989). The neuroendocrine effects of interleukin-2 treatment. J. Clin. Endocrinol. Metab., 69, 402–410.
5. DILLMAN, R.O., OLDHAM, R.K., TAUER, K.W., ORR, D.W., BARTH, N.M., BLUMENSCHEIN, G., ARNOLD, J., BIRCH, R. & WEST, W.H. (1991). Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a national biotherapy study group trial. J. Clin. Oncol., 9, 1233–1240.
6. GRIMM, E.A., MAZUMDER, A., ZHANG, H Z. & ROSENBERG, S.A. (1982). Lymphokine-activated killer cell phenomenon. J. Exp. Med., 155, 1823–1841.
7. LISSONI, P., BARNI, S., ARCHILI, C., CATTANEO, G., ROVELLI, F., CONTI, A., MAESTRONI, G.J.M. & TANCINI, G. (1990). Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res., 10, 753–758.
8. LISSONI, P., TISI, E., BRIVIO, F., BRANI, S., ROVELLI, F., PEREGO, M. & TANCINI, G. (1991). Increase in soluble interleukin-2 receptor and neopterin serum levels during the immunotherapy of cancer with interleukin-2. Eur. J. Cancer, 27, 1014–1016.
9. LISSONI, P., BARNI, S., ARDIZZOIA, A., BRIVIO, F., TANCINI, G., CONTI, A. & MAESTRONI, G.J.M. (1992). Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients. J. Biol. Regul. Homeost. Agents, 6, 132–136.
10. LISSONI, P., BARNI, S., ROVELLI, F., BRIVIO, F., ARDIZZOIA, A., TANCINI, G., CONTI, A. & MAESTRONI, G.J.M. (1993). Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. Eur. J. Cancer, 29A, 185–189.
11. MAESTRONI, G.J.M., CONTI, A. & PIERPAOLI, W. (1986). Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J. Neuroimmunol., 13, 19–25.
12. RITCHIE, A.W., OSWALD, I., MICKLEM, H.S., BOYD, J.E., ELTON, R.A., JAZWINSKA, E. & JAMES, K. (1983). Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br. J. Med., 286, 1773–1776.
13. STEIN, R.C., MALKOVSKA, V., MORGAN, S., GALAZKA, A., ANISZEWSKI, C., ROY, S.E., SHEARER, R.J., MARSDEN, R.A., BEVAN, D., GORDON-SMITH, E.C. & COOMBES, R.C. (1991). The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br. J. Cancer, 63, 275–278.
14. WEST, W.H. (1989). Continuous infusion recombinant interleukin-2 in adoptive cellular therapy of renal carcinoma and other malignancies. Cancer Treat. Rev., 16 (Suppl. A), 83–89.